Work

Host Langerhans cells (LCs) can be therapeutically manipulated In vivo with imiquimod (TLR7 agonist) to augment DLI-mediated GVH and GVL reactivity

Year: 2006

Type: article

Abstract: We recently found in murine models that after MHC-matched allografting, the residual host LCs, the major dendritic cells (DCs) of the skin, survive in epidermis despite the presence of large numbers of peripheral donor T cells in the graft and conversion to the full donor DC chimerism in blood. This observation led us to hypothesize that in vivo manipulation of residual host LCs, which persist in complete donor chimeras after MHC-matched allografting, may have a central role in augmenting DLI-mediated alloimmune responses.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2005.11.164

Authors: M. Skarica, V. Radojcic, L. Luznik

Institutions: Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650